PMID- 11455225
OWN - NLM
STAT- MEDLINE
DCOM- 20011018
LR  - 20171101
IS  - 0378-584X (Print)
IS  - 0378-584X (Linking)
VI  - 24
IP  - 3
DP  - 2001 Jun
TI  - Which factors render cost-covering lump-sum charging difficult for the treatment 
      of patients with acute leukemias?
PG  - 292-4
AB  - BACKGROUND: Growing budget limitations and the planned charging subject to 
      Diagnosis-Related Groups (DRG) points raise the question as to what costs are 
      incurred by the induction therapy and early consolidation treatment of patients 
      with acute myeloid leukemias (AML) and whether these can be compensated in a 
      cost-covering manner by a system based on DRG points. PATIENTS AND METHODS: For 
      100 patients recruited within the framework of the "Kooperative AML-Studie 96" of 
      the Suddeutsche Hamoblastosegruppe a process cost analysis was made between 1996 
      and 1999. All manpower and material costs incurred in the department itself and 
      in the secondary services departments as well as the basic cost shares were 
      recorded taking into due account the length of stay. The cost breakdown was 
      effected based on a double induction therapy and one early consolidation 
      treatment. RESULTS: It turns out that substantial differences exist between lower 
      und upper limits of the length of stay and costs. For all three therapy blocks 
      for patients up to 60 years the cost spread varies between 63 and 204 kDM with a 
      median of 105 kDM, and for older patients between 55.6 and 146.6 kDM with a 
      median of 87.6 kDM. On average, the costs subject to length of stay were roughly 
      70%. CONCLUSIONS: As the costs per case are subject to a spread and, for this 
      relatively small group of patients, are extremely high, the fixing of a 
      case-related lump sum is problematic, the more so as age of patient, comorbidity, 
      type of therapy, ist outcome, and therapy-induced complications represent 
      decisive influencing factors.
CI  - Copyright 2001 S. Karger GmbH, Freiburg
FAU - Kuse, R
AU  - Kuse R
AD  - Hamatologische Abteilung, Allgemeinen Krankenhauses St. Georg, Lohmuhlenstrasse 
      5, D-20099 Hamburg, Germany.
FAU - Colberg, H
AU  - Colberg H
FAU - Marbe, W
AU  - Marbe W
FAU - Kodalle, O
AU  - Kodalle O
FAU - Kalmar, P
AU  - Kalmar P
FAU - Lohfert, C
AU  - Lohfert C
LA  - eng
LA  - ger
PT  - Journal Article
PL  - Switzerland
TA  - Onkologie
JT  - Onkologie
JID - 7808556
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*economics/therapeutic use
MH  - Costs and Cost Analysis
MH  - Diagnosis-Related Groups/*economics
MH  - Female
MH  - Germany
MH  - Hospital Costs/*statistics & numerical data
MH  - Humans
MH  - Length of Stay/economics
MH  - Leukemia, Myeloid, Acute/drug therapy/*economics
MH  - Male
MH  - Middle Aged
MH  - National Health Programs/*economics
EDAT- 2001/07/17 10:00
MHDA- 2001/10/19 10:01
CRDT- 2001/07/17 10:00
PHST- 2001/07/17 10:00 [pubmed]
PHST- 2001/10/19 10:01 [medline]
PHST- 2001/07/17 10:00 [entrez]
AID - 55095 [pii]
AID - 10.1159/000055095 [doi]
PST - ppublish
SO  - Onkologie. 2001 Jun;24(3):292-4. doi: 10.1159/000055095.